

RESULTS OF ANNUAL GENERAL MEETING

Perth, Australia; 27 October 2021: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) advises that its 2021 Annual General Meeting was held today, 27 October 2021. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

Poll Results

Resolutions		For		Against		Abstain
		Number	%	Number	%	Number
1	Non-Binding Resolution to adopt Remuneration Report	18,996,688	89.34	2,267,169	10.66	546,483
2	Re-election of Mr. Qi Xiao Zhou as a Director	29,684,882	99.00	301,358	1.00	472,460
3	Approval of additional 10% Placement Capacity	28,699,679	94.66	1,618,881	5.34	140,140
4	Renewal of proportional takeover provisions in the Constitution	29,615,835	98.33	503,747	1.67	339,118

Proxy Votes Received

Resolutions		For	Against	Proxyholder discretion	Abstain
1	Non-Binding Resolution to adopt Remuneration Report	15,573,166	3,365,169	414,286	546,483
2	Re-election of Mr. Qi Xiao Zhou as a Director	27,362,160	301,358	411,486	472,460
3	Approval of additional 10% Placement Capacity	25,284,957	2,716,881	405,486	140,140
4	Renewal of proportional takeover provision in Constitution	27,299,113	503,747	405,486	339,118

Release authorised by:

Simon Robertson
Company Secretary, Orthocell Ltd



For more information, please contact:

General & Investor enquiries

Paul Anderson

Orthocell Limited

Managing Director

P: +61 8 9360 2888

E: paul.anderson@orthocell.com.au

Media enquiries

Haley Chartres

HACK Director

P: +61 423 139 163

E: haley@hck.digital

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of dental, nerve and orthopaedic, reconstructive applications. Orthocell recently received FDA 510(k) approval for Striate+, the first application of the CelGro® platform for dental GBR applications. Striate+ is also approved in Australia (ARTG) and Europe (CE Mark) for the same. The Company's other major products are the cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue respectively. Orthocell is moving forward with Ortho-ATI® clinical studies designed to assist in the US (FDA) approval process and has completed its pre-IND meetings with the FDA.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

